Evidence map›Paper›PMID 38240343›Full record

ReviewCancer medicine2024

Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews.

Adam Todd, Catherine Waldron, Lucy McGeagh, Ruth Norris, Iakov Bolnykh, Sarah Jane Stewart, Joanna Slodkowska-Barabasz, Zoe Moon, Caitriona Cahir, Sue Thompson and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. The Missing Dimension in Cancer Education: Developmental Meaning-Making and the Expert's Illusion of Symmetry.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adam ToddNewcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-1496-9341
Catherine WaldronRoyal College of Surgeons in Ireland, Dublin, Ireland.
Lucy McGeaghOxford Brookes University, Oxford, UK.
Ruth NorrisNewcastle University, Newcastle upon Tyne, UK.
Iakov BolnykhNewcastle University, Newcastle upon Tyne, UK.
Sarah Jane StewartUniversity College London, London, UK.
Joanna Slodkowska-BarabaszOxford Brookes University, Oxford, UK.
Zoe MoonUniversity College London, London, UK.
Caitriona CahirRoyal College of Surgeons in Ireland, Dublin, Ireland.
Sue ThompsonNewcastle University, Newcastle upon Tyne, UK.
Victoria HarmerImperial College Healthcare NHS Trust, London, UK.
Mary WellsImperial College Healthcare NHS Trust, London, UK.
Eila WatsonOxford Brookes University, Oxford, UK.
Linda SharpNewcastle University, Newcastle upon Tyne, UK.
SWEET Research Team

Funding

Programme Grants for Applied Research NIHR200098
6 · The paper itself

Abstract

backgroundIn oestrogen-receptor positive breast cancer, daily oral adjuvant endocrine therapy (ET) for at least 5 years significantly reduces risks of recurrence and breast cancer-specific mortality. However, many women are poorly adherent to ET. Development of effective adherence support requires comprehensive understanding of influences on adherence. We undertook an umbrella review to identify determinants of ET adherence.

methodsWe searched PubMed, Embase, CINAHL, PsycINFO, Cochrane and PROSPERO (inception to 08/2022) to identify systematic reviews on factors influencing ET adherence. Abstracted determinants were mapped to the World Health Organization's dimensions of adherence. Reviews were quality appraised and overlap assessed.

resultsOf 5732 citations screened, 17 reviews were eligible (9 quantitative primary studies; 4 qualitative primary studies; 4 qualitative or quantitative studies) including 215 primary papers. All five WHO dimensions influenced ET non-adherence: The most consistently identified non-adherence determinants were patient-related factors (e.g. lower perceived ET necessity, more treatment concerns, perceptions of ET 'cons' vs. 'pros'). Healthcare system/healthcare professional-related factors (e.g. perceived lower quality health professional interaction/relationship) were also important and, to a somewhat lesser extent, socio-economic factors (e.g. lower levels of social/economic/material support). Evidence was more mixed for medication-related and condition-related factors, but several may be relevant (e.g. experiencing side-effects, cost). Potentially modifiable factors are more influential than non-modifiable/fixed factors (e.g. patient characteristics).

conclusionsThe evidence-base on ET adherence determinants is extensive. Future empirical studies should focus on less well-researched areas and settings. The determinants themselves are numerous and complex in indicating that adherence support should be multifaceted, addressing multiple determinants.

Indexed as

Breast NeoplasmsBreastCombined Modality TherapyEconomic FactorsFemaleHumansadherencearomatase inhibitorsbreast cancerdeterminantsendocrine therapytamoxifen

Identifiers

PMID38240343
PMCPMC10905548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.